Trial · NCT00518713
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). | 4-week baseline period and 12-week maintenance period | Modified Intent-to-Treat (MITT) population | Percent Reduction | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Reduction in Number of Drop Seizures (First 4 Weeks of the 12-week Maintenance Period). | 4-week baseline period and the first 4 weeks of the 12-week maintenance period | MITT population | Percent reduction | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Reduction in Number of Drop Seizures (Middle 4 Weeks of the 12-week Maintenance Period). | 4-week baseline period and the middle 4 weeks of the 12-week maintenance period | Percent reduction | LEAST_SQUARES_MEAN | |
| SECONDARY | Percent Reduction in Number of Drop Seizures (Last 4 Weeks of the 12-week Maintenance Period). | 4-week baseline period and the last 4 weeks of the 12-week maintenance period | Percent reduction | LEAST_SQUARES_MEAN | |
| SECONDARY | Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (12-week Maintenance Period). | 4-week baseline period and the 12-week maintenance period | Percent of responders | NUMBER | |
| SECONDARY | Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (First 4 Weeks of the 12-week Maintenance Period). | 4-week baseline period and the first 4 weeks of the 12-week maintenance period | MITT | Percent of responders | NUMBER |
| SECONDARY | Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (Middle 4 Weeks of the 12-week Maintenance Period). | 4-week baseline period and the middle 4 weeks of the 12-week maintenance period | Percent Responders | NUMBER | |
| SECONDARY | Percent of Patients Considered Treatment Responders Defined as Those With a >=25%, >=50%, >=75%, 100% Reduction in Drop Seizures (Last 4 Weeks of the 12-week Maintenance Period). | 4-week baseline period and the last 4 weeks of the 12-week maintenance period | Percent Responders | NUMBER | |
| SECONDARY | Tolerance | 4-week baseline period and first 4/first 8 weeks of the maintenance period | MITT | Participants | NUMBER |
| SECONDARY | Investigator Global Evaluations of the Patient's Overall Change in Symptoms. | Week 15 | Those patients in the MITT population who completed a Physician Global Evaluation at Week 15. | participants | NUMBER |
| SECONDARY | Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms. | Week 15 | Those patients in the MITT population who had a baseline and Week 15 parent/caregiver global evaluations were analyzed. | participants | NUMBER |
| OTHER_PRE_SPECIFIED | Percent Reduction in the Number of Non-drop Seizures. | 4-week baseline period and the 12-week maintenance period | Percent reduction | LEAST_SQUARES_MEAN | |
| OTHER_PRE_SPECIFIED | Percent Reduction of Total (Drop and Non-Drop) Seizures. | 4-week baseline period and 12-week maintenance period | Percent reduction | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00518713/outcomes